John F. Milligan

John F. Milligan is an American former executive who was the CEO of Gilead Sciences, a biotechnology company based in the United States from 2016 to 2019. He was previously appointed President of the company and had maintained that role since May 2008. He held various other positions during his tenure with Gilead including COO and CFO and originally joined the biotechnology company in 1990 as a research scientist. Milligan became CEO when former CEO John C. Martin was appointed as Executive Chairman.

Education

Milligan received his bachelor's degree from Ohio Wesleyan University and doctorate from the University of Illinois-Urbana-Champaign.

Career

Upon joining Gilead in 1990, Milligan has served multiple roles at the biotechnology company. After starting out as a research scientist, he has taken on leadership positions within the company which included Director of Project Management for the drug collaboration of Tamiflu with Hoffman-La Roche in 1996.